Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Outcomes and Predictors of Response to Levodopa-Entacapone-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: A Retrospective Cohort Study over a 4-Year Period.

Pharmaceutics·2026
Same author

Dynamic Echocardiographic Changes Induced by Exercise in Healthy, Young Individuals with Early Repolarization Pattern.

Diagnostics (Basel, Switzerland)·2025
Same author

Exercise-Induced Electrocardiographic Changes in Healthy Young Males with Early Repolarization Pattern.

Diagnostics (Basel, Switzerland)·2024
Same author

Levodopa-Entacapone-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease: A Single Center Real-World Experience.

Pharmaceutics·2024
Same author

The role of detailed medical history for the early diagnosis of familial bradycardia in a patient with associated atrial fibrillation: case report.

European heart journal. Case reports·2024
Same author

Total 25-Hydroxyvitamin D Is an Independent Marker of Left Ventricular Ejection Fraction in Heart Failure with Reduced and Mildly Reduced Ejection Fraction.

Biomolecules·2023

Related Experiment Videos

Microbiome-Associated Drug Response Variability in Heart Failure Treatment.

Andrea Rab1, Annamária Magdás2,3, Attila Frigy2,4

  • 1Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania.

Life (Basel, Switzerland)
|May 27, 2026
PubMed
Summary

The gut microbiome impacts heart failure drug effectiveness. Understanding these interactions can personalize treatments and improve patient outcomes by tailoring therapies to individual gut bacteria.

Keywords:
cardiovascular medicationgut microbiomeheart failuremetabolitespersonalized medicinepharmacomicrobiomics

Related Experiment Videos

Area of Science:

  • Cardiovascular Medicine
  • Microbiology
  • Pharmacology

Background:

  • Gut microbiome alterations are linked to cardiovascular diseases like heart failure (HF).
  • Microbial dysbiosis impacts gut barrier function, inflammation, and metabolite production (TMAO, SCFAs, BAs), affecting cardiovascular health.
  • The interplay between HF pharmacotherapy and the gut microbiome is not fully understood.

Purpose of the Study:

  • To review the bidirectional relationship between heart failure medications and gut microbiome composition.
  • To explore how microbial communities influence drug efficacy and safety in HF management.
  • To highlight the potential of microbiome-informed precision medicine in HF.

Main Methods:

  • This is a narrative review synthesizing existing research.
  • Evidence on drug-microbiome interactions in HF was collected and analyzed.
  • Key findings on drug pharmacokinetics, efficacy, and microbiome modulation were summarized.

Main Results:

  • Heart failure drugs exhibit microbiome-dependent pharmacokinetics; for example, digoxin is inactivated by *Eggerthella lenta*.
  • Angiotensin-converting enzyme inhibitors and beta-blockers show varied efficacy influenced by *Firmicutes* populations.
  • Newer HF therapies like SGLT2 inhibitors and MRAs possess beneficial microbiome-modulating effects.
  • Probiotics may mitigate drug-induced gut injury and restore homeostasis.

Conclusions:

  • The gut microbiome significantly influences heart failure pharmacotherapy, affecting drug efficacy and safety.
  • Personalized medicine approaches incorporating microbiome data hold promise for optimizing HF management.
  • Further research with standardized methods and prospective trials is needed to validate pharmacomicrobiomics in HF.